GDNF as a candidate striatal target-derived neurotrophic factor for the development of substantia nigra dopamine neurons.

Abstract

Glial cell line-derived neurotrophic factor (GDNF) has been known for many years to protect and restore dopamine neurons of the substantia nigra (SN) in lesion models of parkinsonism, but much less has been known of its normal physiologic role. We have found that GDNF injected into the striatum postnatally suppresses naturally-occurring cell death in SN dopamine neurons, and neutralizing antibodies augments it. Neutralizing antibodies augment cell death during the first phase, which occurs during the first postnatal week, but not during the second phase in the second week. To further explore the possible neurotrophic role of GDNF, we created double transgenic mice which overexpress GDNF exclusively in the target regions of mesencephalic neurons, particularly the striatum. As anticipated for a limiting, target-derived factor, this resulted in an increased surviving number of SN dopamine neurons after the first phase of cell death. However, this increase did not persist into adulthood. We conclude that GDNF is the leading candidate for a target-derived neurotrophic factor for SN dopamine neurons during the first phase of cell death, but that other factors must play an essential role in later development.